ClinicalTrials.gg
CompletedNCT03319810Updated Jun 25, 2019Results posted

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

A Phase 2 interventional study of Octagam 10% in Mild Cognitive Impairment, sponsored by Sutter Health. Completed at 1 site in United States. Open to participants aged 50 Years to 84 Years. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by Sutter Health · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
50 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,421 studies in Cognitive Dysfunction with a site in United States — 329 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Enrollment
1,097th of 1,146
5 · median 59
Started
2018
with 83 others
Phase 2
198 of 1,421
37 open now
Registered
515th of 1,421
by date

Among the 1,421 studies in Cognitive Dysfunction with a site in United States, this one is the 1,097th largest by enrollment of the 1,146 interventional ones that give a count, is one of 84 that started in 2018, is one of 198 in phase 2, and was the 515th registered.

Cognitive Dysfunction

3,881 studies on the registry are indexed under Cognitive Dysfunction; 1,122 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

329 of the 1,421 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

324 more — sign in →

All 329 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: 50 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,421 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

This is a proof of concept study to determine if changes in brain amyloid levels are evident three months after infusion of 0.4 g/kg of IVIG every 14 days x 5 infusions. Amyloid levels will be measured by Florbetapir PET and retinal scan.

Read the detailed description

Study design:

This is a single center, open label, proof of concept, out-patient study. Subjects will undergo Florbetapir PET and have retinal amyloid levels measured, receive an infusion of IVIG at 0.4 g/kg every 14 days for a total of five infusions, and repeat PET and retinal amyloid measures three months after the first infusion.

Subject population:

The study population will consist of male and female subjects diagnosed with mild cognitive impairment (MCI) due to Alzheimer disease (AD).

Estimated study duration:

The duration of each study subject is approximately 4 months, including one screening visit over a period of approximately 28 days, 5 days of infusions over a 2-month period of time, and a follow-up visit at 3 months after the first infusion.

Description of study drug:

Octagam is an FDA approved 10% human normal immunoglobulin solution ready for intravenous administration.

Study drug dosage:

The dose level of IVIG at 0.4 g/kg will be administered by IV infusion once every 14 days for two months.

Concomitant therapy:

Concomitant medications will be assessed at all study visits. Concomitant medications are prescribed or over-the-counter medications and should be consistent with the inclusion/exclusion criteria. Concomitant medication appropriate to the subject's condition may be prescribed during the course of the study with the exception of those listed above.

Routine vaccinations (i.e., flu vaccination) with commercially available therapeutics are permitted but must not be given within four weeks before or after the administration of the study drug.

Evaluations by visit:

Screening procedures at visit 1 will take place up to 28 days prior to Visit 2 (Day 1) dosing. Screening labs and assessments will be performed during the screening period. The first dose of study drug is administered on Day 1. Visits 2 through 6 have a ±1 day window and occur every 14 days over two months. The investigator will determine if a subject is suitable to continue following a missed infusion. Visit 7 has a ±7 day window.

All study screening data from Visit 1 including laboratory results must be reviewed for study eligibility prior to receiving first dose of study drug. Prior to infusion, a review of concomitant medications and AEs takes place. If the subject continues to be eligible for enrollment, the subject will be infused with study medication and will remain in the infusion clinic for at least 1 hour following the infusion for safety assessments on Visit 2 (Day 1), and 15 minutes for the subsequent visits.

03

Conditions studied

  • Mild Cognitive Impairment

Keywords

  • MCI, Alzheimer Disease, AD
04

Who can participate

Ages eligible
50 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 50 to \<85 years.
  2. Evidence of amyloid pathology on Florbetapir PET at screening.
  3. Diagnosis of MCI due to AD based on NIA-AA criteria. (APPENDIX A)
  4. MRI brain (with past 24 months) which shows evidence of mild hippocampal atrophy and/or bilateral parietal atrophy.
  5. CDR score of 0.5
  6. (MMSE) score of 24-30, inclusive.
  7. Rosen Modified Hachinski Ischemic score ≤4.
  8. Receiving stable doses of medication(s) for the treatment of non-excluded medical condition(s) for at least 30 days prior to screening. Cholinesterase inhibitors and memantine are allowed if doses have stable been least 30 days prior to screening.
  9. Agree to refrain from participating in any treatment or clinical trial targeting amyloid for the duration of the study.
  10. Agree to refrain from taking any herbal supplement considered to enhance cognition unless approved by the investigator for the duration of the study.
  11. Ability to attend all clinical visits and have an informant capable of accompanying the subject on specific clinic visits.
  12. The subject's collaborative informant (support person) must be someone who has known the subject for at least 4 years and has had approximately 2 or more separate communications with the study participant per month (at least one of these communications in person).
  13. Fluency in English and evidence of adequate premorbid intellectual functioning.
  14. Adequate manual dexterity, visual, and auditory abilities to perform all aspects of the cognitive and functional assessments.
  15. Venous access suitable for repeated infusions and phlebotomy.
  16. In the opinion of the investigator, the subject and informant will be compliant and have a high probability of completing the study, including all scheduled evaluations and required tests.

Exclusion criteria

Exclusion Criteria:

  1. Has significant neurological disease other than MCI that in the opinion of the investigator may affect cognition.
  2. History of clinically evident stroke or history of carotid or vertebrobasilar stenosis or plaque.
  3. History of seizures, excluding febrile seizures in childhood.
  4. History of screening visit brain MRI scan indicative of any other significant abnormality, including but not limited to multiple microhemorrhages (2 or more), history or evidence of a single prior hemorrhage > 1 cm3, multiple lacunar infarcts (2 or more) or evidence of a single prior infarct > 1 cm3, evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or space occupying lesions of significance as determined by the PI (e.g., arachnoid cysts or brain tumors such as meningioma).
  5. Brain MRI shows moderate or severe cortical or hippocampal atrophy.
  6. Sensitivity to Florbetapir.
  7. Other present/planned ionized radiation that, in combination with planned exposure to PET ligands for this study, would result in cumulative exposure that would exceed recommended limits.
  8. Ophthalmologic condition that would interfere with retinal amyloid imaging.
  9. Current presence of a clinically significant major psychiatric disorder (e.g., Major Depressive Disorder) according to the criteria of the , Fourth Edition (DSM-IV-TR) or symptom (e.g., hallucinations) that in the opinion of the investigator could affect the subject's ability to complete the study.
  10. Current clinically significant systemic illness that is likely to result in deterioration of the subject's condition or affect the subject's safety during the study including but not limited to renal failure or myocardial infarction.
  11. History of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma, and squamous cell carcinoma of the skin.
  12. Uncontrolled hypertension (diastolic BP> 100 mmHg or systolic BP> 160 mmHg, sitting).
  13. History or evidence of any clinically significant disease or disorder of the immune system (e.g., Crohn's Disease, Rheumatoid Arthritis)
  14. Clinically significant infection within the last 30 days (e.g., chronic persistent or acute infection (eg, upper respiratory infection [URI], urinary tract infection [UTI]).
  15. Female subjects of .
  16. Other clinically significant abnormality on physical, neurological, laboratory, vital signs or examination (e.g., atrial fibrillation) that could compromise the study or be detrimental to the subject.
  17. Weight greater than 120 kg (264 lbs).
  18. Excessive smoking defined as more than 20 cigarettes per day.
  19. History of alcohol or drug dependence or abuse as defined by DSM-IV criteria within the last 2 years.
  20. Severe liver or kidney disease verified by the PI review of , AST and creatinine.
  21. Known coagulopathy, thrombosis, or low count.
  22. less than 11 g/dL.
  23. Known deficiency to IgA.
  24. Positive serology for or C, or .
  25. History of anti-amyloid treatment, immunotherapy, or other experimental treatment for MCI or Alzheimer disease.
  26. Concurrent use of anticholinergic drugs including diphenhydramine.
  27. Current use of anticoagulant medications (except the use of aspirin 325 mg/day or less, plavix, aggrenox, and persantine but not for stroke).
  28. Concurrent use of opioid pain relievers and related synthetic derivatives.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    infusion of IVIG

    Biological: Octagam 10%

Interventions

  • BiologicalOctagam 10%

    FDA approved human normal immunoglobulin solution ready for intravenous administration

06

What researchers measure

Primary outcomes

  1. Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months

    Amyloid deposition in the brain is thought to lead to the development of cognitive decline and conversion to AD. Each participant's amyloid burden can also be quantified through the computation of a Standard Uptake Value ratio (SUVr).

    Time frame: Baseline to 3 months

  2. Change in Baseline Retinal Amyloid Imaging (RAI) at 3 Months

    This is a noninvasive imaging technique that can detect amyloid-beta deposition in the retinas of the eye.

    Time frame: Baseline to 3 months

07

Results

Posted Apr 16, 2019
Limitations and caveats
Small number of subjects analyzed.

Participant flow

Participant flow — Overall Study
MilestoneInfusion of IVIG
Started5
Completed5
Not completed0

Outcome measures

PrimaryChange in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months

Amyloid deposition in the brain is thought to lead to the development of cognitive decline and conversion to AD. Each participant's amyloid burden can also be quantified through the computation of a Standard Uptake Value ratio (SUVr).

Time frame:
Baseline to 3 months
Reported as:
Mean · standard uptake value ratio
Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months
standard uptake value ratioInfusion of IVIG
Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months-3.83 ± 2.84
PrimaryChange in Baseline Retinal Amyloid Imaging (RAI) at 3 Months

This is a noninvasive imaging technique that can detect amyloid-beta deposition in the retinas of the eye.

Time frame:
Baseline to 3 months
Reported as:
Mean · autofluorescent spot count
Change in Baseline Retinal Amyloid Imaging (RAI) at 3 Months
autofluorescent spot countInfusion of IVIG
Right Eye-33.00 ± 68.52
Left Eye-55.75 ± 46.95

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infusion of IVIG0/5 (0%)0/5 (0%)1/5 (20%)
Most frequent other events
Most frequent other events
EventInfusion of IVIG
dizzinessGeneral disorders1/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Infusion of IVIG
Mean74.30 ± 5.27
Sex: Female, Male
Sex: Female, Male(Participants)Infusion of IVIG
Female2
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Infusion of IVIG
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White5
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Infusion of IVIG
United States5
Standard Uptake Value Ratio (SUVr)
Standard Uptake Value Ratio (SUVr)(standard uptake value ratio)Infusion of IVIG
Mean1.57 ± 0.16
08

Study locations

1 site
  • Sutter Neuroscience Medical Group
    Sacramento, California 95816, United States
09

References and documents

Publications

  • Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Chan M, Ghassemi A. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):106-112. doi: 10.1136/jnnp-2015-311486. Epub 2015 Sep 29. PubMed 26420886 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jul 2018, 6 months.

Results were first posted in Apr 2019, 8 months after primary completion.

Of 145 non-industry phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 64. This study's 6 months is below that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2017
First posted
Oct 24, 2017
StartActual
Jan 4, 2018
Primary completionActual
Jul 19, 2018
CompletionActual
Jul 19, 2018
Results first posted
Apr 16, 2019
Last update
Jun 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03319810
Lead sponsor
Sutter Health
Responsible party
Shawn Kile, M.D. (Principal Investigator, Sutter Health) — Principal investigator
First posted
Oct 24, 2017
Start date
Jan 4, 2018
Primary completion
Jul 19, 2018
Completion
Jul 19, 2018
Results posted
Apr 16, 2019
Last update
Jun 25, 2019

Study contacts

Shawn Kile, MD
principal investigator · Sutter Health
Carol Parise, PhD
study director · Sutter Health

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octagam

Start the discussion